Florian Kron

University of Applied Sciences
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Invasive fungal infections such as candidemia and invasive candidiasis are associated with prolonged hospital stays due to the consistent need for treatment and high mortality rates. Consequently, they pose major challenges for the healthcare system in general and hospitals in particular. In contrast to the actual necessary daily infusion of conventional antimycotics, innovative antimycotics such as rezafungin offer potential for early outpatient treatment. By shifting treatment to the outpatient care sector at an earlier stage, both inpatient resources can be relieved, and the efficiency of care can be increased. Particularly in the context of the planned hospital reform, new trans-sectoral care models are crucial for service providers to cope with the increasing economic pressure. This requires close cooperation from a clinical, pharmaceutical as well as economic perspective to successfully integrate innovative therapies into patient care.

Year:

2025

Purpose Next-generation sequencing (NGS) tools have clinical advantages over blood culture but are more expensive. This study assesses the budget impact and break-even point of NGS testing costs from a healthcare provider’s perspective in Germany. Methods The budget impact was calculated based on aggregated data of German post-operative surgery cases. Simulated cost savings were calculated based on a simulated reduction in hospital length of stay (LOS) of four or eight days with a positivity rate of 71% and compared to the costs of one (scenario A) or two tests (scenario B) per case. Furthermore, the break-even point of the cost of two tests compared to saved costs through shortened LOS was conducted. Results For 9,450 cases, an average budget impact for scenario A and scenario B of €1,290.41 [95% CI €1,119.64 – €1,461.19] and - €208.59 [95% CI - €379.36 – - €37.81] was identified for gastrointestinal and kidney surgery cases, and €1,355.58 [95% CI €1,049.62 – €1,661.55] and €18.72 [95% CI - €324.69 – €287.24] for vascular artery surgery cases, respectively. The break-even analysis showed that using two tests per case could achieve a minimum positive contribution margin with an average of 1.9 tests per case across the study population. Conclusion The results revealed a positive budget impact for one NGS test and a slightly negative budget impact for two NGS tests per case. Findings suggest that largest cost savings are generated for more severe cases and are highly dependent on the patient population.

Year:

2024

Objectives Novel interventions (axicabtagene ciloleucel [axi‐cel], lisocabtagene maraleucel [liso‐cel], tafasitamab‐lenalidomide [Tafa‐L], polatuzumab‐rituximab‐bendamustine [pola‐BR]) improve clinical outcomes in second‐line (2 L) treatment of transplant‐ineligible patients with early relapse or refractory (R/R) diffuse large B cell lymphoma (DLBCL). The costs vary depending on the respective treatment regimen and the treatment duration, difficult comparability in reimbursement decisions. The objective was to analyze the health economic impacts of novel 2 L interventions and conventional immunochemotherapies (bendamustine‐rituximab [BR], rituximab‐gemcitabine‐oxaliplatin [R‐GemOx]) from a German healthcare payer's perspective as a function of treatment duration. Methods An economic model was developed to compare treatment costs of 2 L interventions depending on the treatment duration. Treatment duration was measured by progression‐free survival (PFS), identified based on a systematic review. Total and average costs were calculated over 5 years to evaluate incremental costs at median PFS for each intervention. Results Average costs per month at median PFS ranged from €2846 (95% CI: 5067‐1641) to €40 535 (95% CI: 91180‐N/A) for BR and liso‐cel, respectively. Incremental costs at the lowest median PFS (R‐GemOx: 5.3 months) revealed −€664, €5560, €11 817, €53 145, and €67 745 for BR, Tafa‐L, pola‐BR, axi‐cel, and liso‐cel as compared to R‐GemOx, respectively. Conclusions Analyses uncovered a variation of incremental costs of 2 L transplant‐ineligible DLBCL interventions as a function of time leading to amortization of high‐priced interventions.

Year:

2024

Value-based healthcare is becoming increasingly important in healthcare. In this approach, patient benefit is considered as the ratio of treatment outcomes to costs, with the aim of (1) improving the quality of care, (2) reducing costs and (3) expanding access to innovative treatments for patients. However, a more detailed analysis of the regulatory assessment and reimbursement processes in Germany reveals „gaps“ that hinder a holistic approach to novel healthcare technologies for value-based healthcare. The current challenges are highlighted with reference to chimeric antigen receptor T-cell therapy (CAR-T cell therapy) and possible solutions and implications for the German healthcare system are identified.

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Oliver A. Cornely

Director

University of Cologne

GERMANY
View details

Julia von Tresckow

University Hospital Essen

GERMANY
View details

Fabian Dusse

Head of Depatment

Kliniken Essen-Mitte

GERMANY
View details

Bastian von Tresckow

University of Cologne

GERMANY
View details

Hans Christian Reinhardt

-

GERMANY
View details